CN102940876B - Application of polypeptide GH27 in preparation of medicament for preventing and treating goat diarrhea - Google Patents
Application of polypeptide GH27 in preparation of medicament for preventing and treating goat diarrhea Download PDFInfo
- Publication number
- CN102940876B CN102940876B CN 201210534909 CN201210534909A CN102940876B CN 102940876 B CN102940876 B CN 102940876B CN 201210534909 CN201210534909 CN 201210534909 CN 201210534909 A CN201210534909 A CN 201210534909A CN 102940876 B CN102940876 B CN 102940876B
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- preventing
- medicament
- preparation
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention relates to application of a polypeptide GH27 in preparation of a medicament for preventing and treating goat diarrhea, and belongs to the technical field of polypeptides. The polypeptide GH27 is obtained by using a conventional chemical synthesis method, the molecular weight of the polypeptide GH27 is 3,084.46Da, the isoelectric point is 11.83, and the amino acid sequence is LVRRKVRQERTISRSKGWIFGEPMGP. The polypeptide GH27 is applied to the preparation of the medicament for preventing and treating the goat diarrhea. The medicament prepared from the polypeptide GH27 and used for preventing and treating the goat diarrhea has an obvious bacteriostatic effect.
Description
Technical field:
The present invention relates to the application of polypeptide GH27 in preparation prevention and treatment goat diarrhoea medicine, belong to the polypeptide technical field.
Background technology:
Antibiotic extensive use, Resistant strain and multiple antibiotic resistant strain increase day by day, and clinical anti-infective therapy faces a severe challenge, seeks antibacterium, the antiviral drugs of broad-spectrum high efficacy, remains a very difficult task.Antibacterial peptide is innate immunity material very important in animal body, is a kind of bioactie agent with high-efficiency antimicrobial, antiviral, immunologic function.Antibacterial peptide is the peptide class active substance of an exogenous pathogen of class antagonism of host's nonspecific immunity system of defense generation, is autarcetic effector molecule.Studies show that, antibacterial peptide has and the diverse mechanism of action of traditional antibiotic, is difficult for the generation of inducible resistance bacterial strain; Has a broad antifungal spectrum all has effect to antibacterial, fungus, virus, protozoon and cancerous cell.On poultry, had been found that the antibacterial peptide of 3 families comprises cathelicidin, liver-expressed antimicrobial peptide (LEAP), and β-defensin.These antibacterial peptides are bacillary for the poultry opposing, viral disease has vital effect.The sudden change of relevant these genes or disappearance will have significant impact for the ability of poultry anti-microbial infection.These a little antibacterial peptides are except having broad spectrum antibiotic activity, also have simultaneously efficient antifungal, antiviral, protozoacide and (or) anti-tumor activity, can kill leptospira as Bat5 and IMc7, Candida albicans, cryptococcus and enveloped virus and parasite are had killing action preferably; Some antibacterial peptides have togavirus that obvious lethality is arranged to herpesvirus, influenza virus, HIV (human immunodeficiency virus) (Human Immunodeficiency Virus) etc.In addition, some antibacterial peptide also has multiple other adjusting function simultaneously, also have the functions such as the wound healing of promotion, tissue injury's reparation, chemical chemotaxis, Angiogensis and parasiticide as Cathelicidin, have important biomolecule to learn on adjusting animal immunity of organism active.
Summary of the invention:
The object of the present invention is to provide the application of polypeptide GH27 in preparation prevention and treatment goat diarrhoea medicine,
Polypeptide GH27 of the present invention adopts the method for conventional chemosynthesis to obtain, and the molecular weight of polypeptide GH27 is 3084.46 Da, and isoelectric point, IP is 11.83, and aminoacid sequence is LVRRKVRQERTISRSKGWIFGEPMGP.
The application of polypeptide GH27 of the present invention in preparation prevention and treatment goat diarrhoea medicine.
The antibacterial tests of polypeptide GH27 of the present invention, its testing program is conventional method, and is specific as follows:
after the high post broth agar culture medium heat fused that has prepared, to be cooled during to 50 ℃ of left and right, add broth bouillon bacterium liquid 1mL (through 37 ℃ of bacterium liquid of cultivating 18 hours of constant temperature), shake gently, make it even. then pour in aseptic plate, rock gently plate, so that culture medium is tiled on plate equably, after to be cooled solidifying, with the tweezers of sterilizing with the dried scraps of paper of penicillin, the dried scraps of paper of streptomycin, the dried scraps of paper of tetracycline, the neat sequential flat blood of putting into of the dried scraps of paper of sulfadiazine, cover the potlery tile lid, having marked mark puts to cultivate after 24 hours .24 hour in 37 ℃ of constant incubators and takes out culture medium, measure the inhibition zone size and record it with slide calliper rule, and more different antibacterials are to the action intensity of different bacterium.
Effect of the present invention is: with prevention and the treatment goat diarrhoea medicine of polypeptide GH27 preparation, fungistatic effect is obvious.
Description of drawings:
Fig. 1 is that polypeptide GH27 is to colibacillary inhibition.
The specific embodiment:
The present invention is described in further detail below in conjunction with accompanying drawing.
The polypeptide GH27 that embodiment adopts obtains with the method for conventional chemosynthesis, and the molecular weight of polypeptide GH27 is 3084.46 Da, and isoelectric point, IP is 11.83, and aminoacid sequence is LVRRKVRQERTISRSKGWIFGEPMGP.
In embodiment, the concrete steps of the antibacterial tests of polypeptide GH27 are with the description of summary of the invention part.
Embodiment 1:
Polypeptide GH27 is to colibacillary inhibitory action.
The polypeptide GH27 that gets 7 μ g/ml and 10 μ g/ml prevention and treatment goat diarrhoea carries out bacteriostatic test.Result is: and the fungistatic effect a little less than the polypeptide GH27 of 7ug/ml prevention and treatment goat diarrhoea only has (Fig. 1-B), clearly (Fig. 1-C), Fig. 1-A is the polypeptide GH27 fungistatic effect experimental control of prevention and treatment goat diarrhoea to the polypeptide GH27 fungistatic effect of 10ug/ml prevention and treatment goat diarrhoea.
Embodiment 2:
The minimum inhibitory concentration of polypeptide GH27 to different bacterium.
The polypeptide GH27 that gets variable concentrations suppresses respectively escherichia coli, bacillus pyocyaneus, gold-coloured staphylococci, bacillus subtilis and Candida albicans.Wherein table 1 be this polypeptide to escherichia coli, bacillus pyocyaneus, gold-coloured staphylococci, the minimum inhibitory concentration of bacillus subtilis and Candida albicans is respectively: 4.91 μ g/ml, 12.74 μ g/ml, 9.46 μ g/ml, 24.93 μ g/ml, 21.58 μ g/ml.
Table 1
SEQUENCE LISTING
＜110〉Kunming Institute of Zoology, Chinese Academy of Sciences
＜120〉application of polypeptide GH27 in preparation prevention and treatment goat diarrhoea medicine
<130> 1
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 26
<212> PRT
<213> Capra ibex
<400> 1
Leu Val Arg Arg Lys Val Arg Gln Glu Arg Thr Ile Ser Arg Ser Lys
1 5 10 15
Gly Trp Ile Phe Gly Glu Pro Met Gly Pro
20 25
Claims (1)
1. molecular weight is 3084.46Da, isoelectric point, IP is 11.83, aminoacid sequence is the application of polypeptide GH27 in preparation prevention and treatment goat diarrhoea medicine of LVRRKVRQERTISRSKGWIFGEPMGP, it is characterized in that described polypeptide GH27 has bacteriostasis to escherichia coli, bacillus pyocyaneus, gold-coloured staphylococci, bacillus subtilis and Candida albicans.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210534909 CN102940876B (en) | 2012-12-12 | 2012-12-12 | Application of polypeptide GH27 in preparation of medicament for preventing and treating goat diarrhea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210534909 CN102940876B (en) | 2012-12-12 | 2012-12-12 | Application of polypeptide GH27 in preparation of medicament for preventing and treating goat diarrhea |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102940876A CN102940876A (en) | 2013-02-27 |
| CN102940876B true CN102940876B (en) | 2013-11-06 |
Family
ID=47723936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210534909 Expired - Fee Related CN102940876B (en) | 2012-12-12 | 2012-12-12 | Application of polypeptide GH27 in preparation of medicament for preventing and treating goat diarrhea |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102940876B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102702333A (en) * | 2012-05-29 | 2012-10-03 | 中国药科大学 | Drug-resistant pathogen infection resistant polypeptide and uses thereof |
| CN102731629A (en) * | 2012-05-21 | 2012-10-17 | 长春普莱医药生物技术有限公司 | Antibacterial peptide and application thereof |
-
2012
- 2012-12-12 CN CN 201210534909 patent/CN102940876B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102731629A (en) * | 2012-05-21 | 2012-10-17 | 长春普莱医药生物技术有限公司 | Antibacterial peptide and application thereof |
| CN102702333A (en) * | 2012-05-29 | 2012-10-03 | 中国药科大学 | Drug-resistant pathogen infection resistant polypeptide and uses thereof |
Non-Patent Citations (3)
| Title |
|---|
| 人工合成抗菌肽对白色念珠菌体外抑制作用的初步研究;孙倩等;《北京口腔医学》;20110428;第19卷(第02期);70-73 * |
| 合成抗菌肽对大肠杆菌的体外抑制作用;孙新婷等;《中国临床药理学杂志》;20041128;第20卷(第06期);437-439 * |
| 抗菌肽的研究现状与展望;韩文瑜，孙长江;《中国兽药杂志》;20091020;第43卷(第10期);11-19 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102940876A (en) | 2013-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Menousek et al. | Database screening and in vivo efficacy of antimicrobial peptides against methicillin-resistant Staphylococcus aureus USA300 | |
| JP6964577B2 (en) | Antibacterial peptide and its usage | |
| Findlay et al. | Cationic amphiphiles, a new generation of antimicrobials inspired by the natural antimicrobial peptide scaffold | |
| CN101155825B (en) | Antimicrobial hexapeptides | |
| KR100891157B1 (en) | Short bioactive peptides and methods for their use | |
| Uzair et al. | Scorpion venom peptides as a potential source for human drug candidates | |
| CN102702333B (en) | Drug-resistant pathogen infection resistant polypeptide and uses thereof | |
| US9273095B2 (en) | Antibiotic peptide and preparation method therefor and application therefor | |
| CN102731629B (en) | Antibacterial peptide and application thereof | |
| BR112012024676B1 (en) | Peptide composition and substrate | |
| Li et al. | An enhanced variant designed from DLP4 cationic peptide against Staphylococcus aureus CVCC 546 | |
| Kang et al. | Effective antimicrobial activity of a peptide mutant Cbf-14-2 against penicillin-resistant bacteria based on its unnatural amino acids | |
| Wang et al. | Housefly Phormicin inhibits Staphylococcus aureus and MRSA by disrupting biofilm formation and altering gene expression in vitro and in vivo | |
| Teixeira et al. | In vivo antimicrobial evaluation of an alanine-rich peptide derived from Pleuronectes americanus | |
| Nguyen et al. | Avian antimicrobial peptides: in vitro and in ovo characterization and protection from early chick mortality caused by yolk sac infection | |
| CN104650208B (en) | Derived peptide of one breeder derived antimicrobial peptide and its preparation method and application | |
| Gogoi et al. | Linear and branched forms of short antimicrobial peptide-IRK inhibit growth of multi drug resistant Staphylococcus aureus isolates from mastitic cow milk | |
| CN102940874B (en) | Application of small molecular polypeptide CW14 in preparation of goat antibacterial medicament | |
| Kim et al. | Effects of the synthetic coprisin analog peptide, CopA3 in pathogenic microorganisms and mammalian cancer cells | |
| Vineethkumar et al. | Post-translationally modified frog skin-derived antimicrobial peptides are effective against Aeromonas sobria | |
| CN104524547B (en) | Application of plectasin in inhibiting streptococcus agalactiae | |
| CN102940876B (en) | Application of polypeptide GH27 in preparation of medicament for preventing and treating goat diarrhea | |
| Gong et al. | Effective Treatment of Helicobacter pylori Infection Using Supramolecular Antimicrobial Peptide Hydrogels | |
| CN102935223B (en) | Application of polypeptide GC25 in preparing anti-infective drug | |
| CN102940877B (en) | Application of polypeptide DM29 in preparing drugs for increasing natural immunity of goats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131106 Termination date: 20141212 |
|
| EXPY | Termination of patent right or utility model |